Salt forms of complement component C5A receptor

By developing multiple salt forms of compound 1, the challenges of delivering compound 1 in the treatment of C5a-mediated diseases were addressed, improving its solubility and bioavailability, and achieving effective drug delivery and therapeutic effects.

CN118908879APending Publication Date: 2024-11-08CHEMOCENTRYX INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410992468.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-11-08
Filing Date
2020-11-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, the efficient delivery of compound 1 faces challenges in delivering biologically relevant amounts, and the development of its salt form has not been reported, affecting its pharmacokinetic properties in the treatment of C5a-mediated diseases.

Method used

Provided are multiple salt forms of compound 1, such as benzenesulfonate, toluenesulfonate, naphthalene disulfonate, naphthalenesulfonate, camphorsulfonate, and ethanedisulfonate, which improve the solubility and bioavailability of the compound, and prepare pharmaceutical compositions for effective delivery.

Benefits of technology

The improved solubility and bioavailability of compound 1 provided an opportunity to prepare drug formulations, enabling compound 1 to achieve effective therapeutic effects and making it suitable for treating a variety of C5a receptor-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908879A_ABST
    Figure CN118908879A_ABST
Patent Text Reader

Abstract

Provided herein are salt forms of complement component 5a receptor having Formula 1. Also provided herein are pharmaceutical compositions and methods of treatment using the salt forms of Compound 1 described herein. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with an application date of November 6, 2020, a national phase entry date of May 9, 2022, an application number of 202080077957.X, and an invention name of “Salt form of complement component C5A receptor”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority under USC §119(e)35 to U.S. Provisional Application Serial No. 62 / 932,658, filed on November 8, 2019, the entire disclosure of which is incorporated herein by reference.

[0004] STATEMENT REGARDING RIGHTS TO INVENTS RESULTING FROM FEDERALLY SPONSORED RESEARCH

[0005] not applicable.

[0006] A referenced "sequence listing", table or computer program listing appendix is ​​submitted on a CD-ROM

[0007] not applicable. Background of the Invention

[0009] The complement system plays a central role in the clearance of immune complexes and in the immune response to infectious agents, foreign antigens, virus-infected cells, and tumor cells. Inappropriate or excessive activation of the complement system can lead to harmful and potentially life-threatening consequences due to severe inflammation and resulting tissue destruction. These consequences manifest clinically in a variety of diseases, including septic shock; myocardial and intestinal ischemia / reperfusion injury; transplant rejection; organ failure; nephritis; pathological inflammation; and autoimmune diseases.

[0010] The complement system consists of a group of proteins that are usually present in the serum in an inactive state. The activation of the complement system mainly includes three different pathways, namely the classical pathway, the alternative pathway and the lectin pathway (VM Holers, Clinical Immunology: Principles and Practice, ed. R R Rich, Mosby Publishing; 1996, 363-391): 1) The classical pathway is a calcium / magnesium-dependent cascade reaction, which is usually activated by the formation of antigen-antibody complexes. It can also be activated in an antibody-independent manner by binding to ligand-complexed C-reactive protein and many pathogens including Gram-negative bacteria. 2) The alternative pathway is a magnesium-dependent cascade reaction, which is activated by the deposition and activation of C3 on certain susceptible surfaces (such as cell wall polysaccharides of yeast and bacteria, and certain biopolymer materials). 3) The lectin pathway involves initial binding of mannose-binding lectin and subsequent activation of C2 and C4, which is common to the classical pathway (Matsushita, M. et al., J. Exp. Med. 176: 1497-1502 (1992); Suankratay, C. et al., J. Immunol. 160: 3006-3013 (1998)).

[0011] Activation of the complement pathway generates biologically active fragments of complement proteins, such as C3a, C4a, and C5a anaphylatoxins and the C5b-9 membrane attack complex (MAC), all of which mediate inflammatory responses by affecting leukocyte chemotaxis; activating macrophages, neutrophils, platelets, mast cells, and endothelial cells; and increasing vascular permeability, cytolysis, and tissue damage.

[0012] Complement C5a is one of the most potent proinflammatory mediators of the complement system. (On a molar basis, the allergic C5a peptide is 100 times more potent than C3a in initiating an inflammatory response.) C5a is the activated form of C5 (190 kD, molecular weight). The content of C5a in human serum is about 80 μg / ml (Kohler, PF et al., Journal of Immunology. 99: 1211-1216 (1967)). It consists of two polypeptide chains α and β, with molecular weights of approximately 115 kD and 75 kD, respectively (Tack, BF et al., Biochemistry 18: 1490-1497 (1979)). C5 is biosynthesized as a single-chain promolecule, which is enzymatically broken down into a double-chain structure during processing and secretion. After cleavage, the two chains are linked together by at least one disulfide bond and non-covalent interactions (Ooi, YM et al., Journal of Immunology. 124: 2494-2498 (1980)).

[0013] Recent studies have identified (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, Compound 1, as useful for treating C5a-mediated diseases. Despite the disclosure of this compound, effective delivery of biologically relevant amounts of Compound 1 remains challenging. Furthermore, the salt form of this compound has not been reported.

[0014]

[0015] Salt forms can improve important biological properties, such as solubility, dissolution rate, and bioavailability, thereby increasing the therapeutic efficacy of such compounds. Therefore, there is a need to provide salt forms of compound 1 that can provide favorable pharmacokinetic properties. The present disclosure addresses these needs and also provides related advantages. Summary of the invention

[0016] The present invention provides a salt form of compound 1 ((2R, 3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl))phenyl)piperidine-3-carboxamide),

[0017]

[0018] In some aspects, the present invention provides a besylate salt of compound 1. In some embodiments, the besylate salt of compound 1 is a single crystalline form substantially free of other crystalline or amorphous forms. In some embodiments, the single crystalline form is besylate salt of compound 1, Form I. In some embodiments, the single crystalline form is besylate salt of compound 1, Form II.

[0019] In some aspects, the present invention provides a tosylate salt of Compound 1. In some embodiments, the tosylate salt of Compound 1 is a single crystalline form substantially free of other crystalline or amorphous forms. In some embodiments, the single crystalline form is Form I of the tosylate salt of Compound 1.

[0020] In some aspects, the present invention provides a naphthalene disulfonate salt of Compound 1. In some embodiments, the naphthalene disulfonate salt of Compound 1 is a single crystalline form substantially free of other crystalline or amorphous forms. In some embodiments, the single crystalline form is Form I of the naphthalene disulfonate salt of Compound 1.

[0021] In some aspects, the present invention provides a naphthalenesulfonate salt of Compound 1. In some embodiments, the naphthalenesulfonate salt of Compound 1 is a single crystalline form substantially free of other crystalline or amorphous forms. In some embodiments, the single crystalline form is Form I of the naphthalenesulfonate salt of Compound 1.

[0022] In some aspects, the present invention provides a camsylate salt of Compound 1. In some embodiments, the camsylate salt of Compound 1 is a single crystalline form substantially free of other crystalline or amorphous forms. In some embodiments, the single crystalline form is Form I of the camsylate salt of Compound 1.

[0023] In some aspects, the present invention provides an edisylate salt of Compound 1. In some embodiments, the edisylate salt of Compound 1 is a single crystalline form substantially free of other crystalline or amorphous forms. In some embodiments, the single crystalline form is Form I of the edisylate salt of Compound 1.

[0024] Each of the provided salt forms can be further characterized as described herein.

[0025] In other aspects, the present invention provides a pharmaceutical composition of a salt form of Compound 1 described herein.

[0026] In other aspects, the present invention provides a method of treating a subject suffering from or susceptible to a disease or condition involving pathological activation of the C5a receptor, comprising administering to the subject an effective amount of a salt form of Compound 1 described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The X-ray powder diffraction (XRPD) pattern of the besylate salt Form I of Compound 1 is shown.

[0029] Figure 2 The differential scanning calorimetry (DSC) thermogram and thermogravimetric analysis (TGA) of the besylate salt Form I of Compound 1 are shown.

[0030] Figure 3 A dynamic vapor sorption (DVS) graph of Form I of the besylate salt of Compound 1 is shown.

[0031] Figure 4 Shown is a representative scanning electron microscope (SEM) image of the besylate salt of Compound 1, Form I. The magnification shown is 5,000X.

[0032] Figure 5 Shown are representative polarized light microscopy (PLM) images of the besylate salt of Compound 1, Form I. The magnification shown is 20X.

[0033] Figure 6 The X-ray powder diffraction (XRPD) pattern of the besylate salt Form II of Compound 1 is shown.

[0034] Figure 7 The differential scanning calorimetry (DSC) thermogram and thermogravimetric analysis (TGA) of the besylate salt Form II of Compound 1 are shown.

[0035] Figure 8 The X-ray powder diffraction (XRPD) pattern of the tosylate salt form I of Compound 1 is shown.

[0036] Fig. 9 The differential scanning calorimetry (DSC) thermogram and thermogravimetric analysis (TGA) of the tosylate salt form I of Compound 1 are shown.

[0037] Fig.10 A dynamic vapor sorption (DVS) graph of Form I of the tosylate salt of Compound 1 is shown.

[0038] Fig.11 Shown is a representative scanning electron microscope (SEM) image of the tosylate salt of Compound 1, Form I. The magnification shown is 1,000X.

[0039] Fig.12 Shown are representative polarized light microscopy (PLM) images of the tosylate salt of Compound 1, Form I. The magnification shown is 10X.

[0040] Fig.13 The X-ray powder diffraction (XRPD) pattern of the naphthalene disulfonate salt Form I of Compound 1 is shown.

[0041] Fig.14 The differential scanning calorimetry (DSC) thermogram and thermogravimetric analysis (TGA) of the naphthalene disulfonate salt Form I of Compound 1 are shown.

[0042] Fig.15 The dynamic vapor sorption (DVS) graph of the naphthalene disulfonate salt Form I of Compound 1 is shown.

[0043] Fig.16 Shown are representative scanning electron microscope (SEM) images of the naphthalene disulfonate salt of Compound 1, Form I. The magnification shown is 2,500X.

[0044] Fig.17 Shown are representative polarized light microscopy (PLM) images of the naphthalene disulfonate salt of Compound 1, Form I. The magnification shown is 20X.

[0045] Fig.18 The X-ray powder diffraction (XRPD) pattern of the naphthalenesulfonate salt Form I of Compound 1 is shown.

[0046] Fig.19 The differential scanning calorimetry (DSC) thermogram and thermogravimetric analysis (TGA) of the naphthalenesulfonate salt Form I of Compound 1 are shown.

[0047] Fig. 20A dynamic vapor sorption (DVS) graph of Form I of the naphthalenesulfonate salt of Compound 1 is shown.

[0048] Fig.21 Shown is a representative scanning electron microscope (SEM) image of the naphthalenesulfonate salt of Compound 1, Form I. The magnification shown is 5,000X.

[0049] Fig. 22 Shown are representative polarized light microscopy (PLM) images of the naphthalenesulfonate salt of Compound 1, Form I. The magnification shown is 10X.

[0050] Fig.23 The X-ray powder diffraction (XRPD) pattern of Form I of the camphorsulfonate salt of Compound 1 is shown.

[0051] Fig.24 The differential scanning calorimetry (DSC) thermogram and thermogravimetric analysis (TGA) of Form I of the camphorsulfonate salt of Compound 1 are shown.

[0052] Fig.25 The dynamic vapor sorption (DVS) graph of Form I of the camphorsulfonate salt of Compound 1 is shown.

[0053] Fig.26 A representative scanning electron microscope (SEM) image of the camphorsulfonate salt of Compound 1, Form I is shown. The magnification shown is 5,000X.

[0054] Fig. 27 Shown are representative polarized light microscopy (PLM) images of the camsylate salt of Compound 1, Form I. The magnification shown is 10X.

[0055] Fig.28 The X-ray powder diffraction (XRPD) pattern of Form I of the edisylate salt of Compound 1 is shown.

[0056] Fig.29 The differential scanning calorimetry (DSC) thermogram of Form I of the edisylate salt of Compound 1 is shown.

[0057] Fig.30 A graph showing the plasma concentration over time in rats administered a liquid suspension containing a crystalline form of Compound 1 (dashed line) and the same amount of a liquid suspension containing various salt forms of Compound 1. Naphthalenesulfonate (solid circles); Camphorsulfonate (open triangles); Naphthalenedisulfonate (open squares); Toluenesulfonate (solid diamonds); Benzenesulfonate (solid squares); Ethylenedisulfonate (open circles). Further formulation details are provided in Example 8.

[0058] Fig.31A graph showing the plasma concentration over time in rats administered a liquid suspension containing a crystalline form of Compound 1 (dashed line) and the same amount of a liquid suspension containing various salt forms of Compound 1. Naphthalenesulfonate (solid circles); Camphorsulfonate (open triangles); Naphthalenedisulfonate (open squares); Toluenesulfonate (solid diamonds); Benzenesulfonate (solid squares); Ethylenedisulfonate (open circles). Further formulation details are provided in Example 9. DETAILED DESCRIPTION OF THE INVENTION

[0060] I.General

[0061] The present invention provides salt forms of Compound 1. These forms advantageously increase the solubility and bioavailability of the compound, providing the opportunity to prepare, for example, pharmaceutical formulations that can deliver biologically relevant amounts of Compound 1 without the need to administer excess liquid or excess capsules.

[0062] II. Definitions

[0063] The terms "about" and "about" used to modify numerical values ​​as used herein represent a close range around the explicit value. If "X" is the value, "about X" or "about X" will represent a value from 0.9X to 1.1X, more preferably, a value from 0.95X to 1.05X. Any reference to "about X" or "about X" specifically represents at least the values ​​X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, and 1.05X. Therefore, "about X" and "about X" are intended to teach and provide written description support for claim limitations such as "0.98X".

[0064] “Compound 1” is a compound, whose IUPAC name is (2R, 3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, and whose structure is shown below:

[0065]

[0066] "Substantially free" refers to amounts of 10% or less of another form, preferably 8%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of another form.

[0067] The neutral forms of Compound 1 can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of Compound 1 differs from the various salt forms in certain physical properties, such as, but not limited to, solubility in polar solvents, but otherwise the salts are equivalent to the parent form of Compound 1 for purposes of the present disclosure.

[0068] The terms "treatment" or "therapy" include disease-modifying treatment and symptomatic treatment, any of which can be prophylactic (i.e., before symptoms appear, to prevent, delay or reduce the severity of symptoms) or therapeutic (i.e., after symptoms appear, to reduce the severity and / or duration of symptoms).

[0069] As used herein, a disorder is considered "responsive to C5a receptor modulation" if modulation of C5a receptor activity results in a decrease in the inappropriate activity of the C5a receptor.

[0070] The term "subject" refers to mammals, including primates (especially humans), domesticated companion animals (such as dogs, cats, horses, etc.) and livestock (such as cattle, pigs, sheep, etc.). Dosages as described herein. In some embodiments, the term "subject" refers to humans.

[0071] III. Detailed Description of the Implementation Scheme

[0072] The present invention provides salt forms of Compound 1, pharmaceutical compositions containing the same, methods of their use, and methods of preparing the salt forms.

[0073] A. Salt Forms of Compound 1

[0074] The present disclosure provides various salt forms of compound 1, including benzenesulfonate, toluenesulfonate, naphthalene disulfonate, naphthalenesulfonate, camphorsulfonate and edisylate. In certain embodiments, a single crystal form of a benzenesulfonate, toluenesulfonate, naphthalene disulfonate, naphthalenesulfonate, camphorsulfonate or edisylate is provided. In certain embodiments, the single crystal form of the salt is substantially free of other crystalline or amorphous forms.

[0075] In some embodiments, the besylate salt of Compound 1 has the formula:

[0076]

[0077] In some embodiments, the tosylate salt of Compound 1 has the formula:

[0078]

[0079] In some embodiments, the naphthalenedisulfonate salt of Compound 1 has the formula:

[0080]

[0081] In some embodiments, the naphthalenesulfonate salt of Compound 1 has the formula:

[0082]

[0083] In some embodiments, the camphorsulfonate salt of Compound 1 has the formula:

[0084]

[0085] In some embodiments, the edisylate salt of Compound 1 has the formula:

[0086]

[0087] The specific salts disclosed herein may exist in one or more polymorphic forms. The individual polymorphs of the salts are identified as Form I, Form II, etc.

[0088] i. Benzenesulfonate salt of compound 1 (form I)

[0089] In some aspects, the present invention provides a benzenesulfonate salt of compound 1, Form I

[0090]

[0091] It is substantially free of other crystalline or amorphous forms of Compound 1.

[0092] In some embodiments, the besylate salt of Compound 1, Form I, is characterized by an X-ray powder diffraction pattern including peaks at 10.9, 13.3, 16.2, 17.6, and 21.8 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the besylate salt of Compound 1, Form I, is further characterized by an X-ray powder diffraction pattern including peaks at 6.6, 7.6, 14.5, 16.2, and 28.2 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the besylate salt of Compound 1, Form I, is characterized by substantially conforming to Figure 1 X-ray powder diffraction pattern of .

[0093] Differential scanning calorimetry (DSC) can also be used to characterize the benzenesulfonate salt form I of compound 1 described herein. In some embodiments, the benzenesulfonate salt form I of compound 1 is characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at about 207.2°C. In some embodiments, the benzenesulfonate salt form I of compound 1 is characterized by a melting point onset of about 200.6°C as determined by a differential scanning calorimetry thermogram (DSC). In some embodiments, the benzenesulfonate salt form I of compound 1 is characterized by substantially conforming to Figure 2 Differential scanning calorimetry (DSC) thermogram.

[0094] Thermogravimetric analysis (TGA) is another technique that can be used to characterize the benzenesulfonate salt Form I of Compound 1 described herein. In some embodiments, the benzenesulfonate salt Form I of Compound 1 is characterized by a weight loss of about 0.14% when heated to about 202.9° C. as measured by thermogravimetric analysis (TGA). In some embodiments, the benzenesulfonate salt Form I of Compound 1 is characterized by substantially conforming to Figure 2 Thermogravimetric analysis (TGA) thermal analysis.

[0095] Dynamic vapor sorption (DVS) is another method that can be used to characterize the benzenesulfonate crystalline form I of compound 1 described herein. In some embodiments, the benzenesulfonate crystalline form I of compound 1 is characterized by a weight gain of about 0.5% after undergoing a dynamic vapor sorption cycle (DVS) from about 0% relative humidity (RH) to about 75% relative humidity at 25°C. In some embodiments, the benzenesulfonate crystalline form I of compound 1 is characterized by a weight gain of about 0.73% after undergoing a dynamic vapor sorption (DVS) cycle from about 5% relative humidity (RH) to about 95% relative humidity at 25°C. In some embodiments, the benzenesulfonate crystalline form I of compound 1 is characterized by substantially meeting Figure 3 Dynamic vapor sorption (DVS) diagram.

[0096] Microscopy can also be used to characterize the benzenesulfonate salt Form I of Compound 1 described herein. In some embodiments, a scanning electron microscope (SEM) is used. In some embodiments, the benzenesulfonate salt Form I of Compound 1 is characterized by having an SEM image of predominantly prismatic or anhedral particles. In some embodiments, the particles are about 1 μm to 73 μm as measured by SEM. In some embodiments, the benzenesulfonate salt Form I of Compound 1 is characterized by substantially conforming to Figure 4 Scanning electron microscope (SEM) image of the .

[0097] Polarized light microscopy (PLM) is another technique that can be used to characterize the besylate salt Form I of Compound 1 described herein. In some embodiments, the besylate salt Form I of Compound 1 is characterized by particles having a size range of about 2.5 to 83 μm as determined by polarized light microscopy (PLM). In some embodiments, the besylate salt Form I of Compound 1 is characterized by particles having a size range of about 2.5 to 83 μm as determined by polarized light microscopy (PLM). Figure 5 Polarized light microscopy (PLM) profile shown.

[0098] ii. Benzenesulfonate salt of compound 1 (form II)

[0099] In some aspects, the present invention provides a benzenesulfonate salt of compound 1, Form II

[0100]

[0101] It is substantially free of other crystalline or amorphous forms of Compound 1.

[0102] In some embodiments, the besylate salt of Compound 1, Form II, is characterized by an X-ray powder diffraction pattern including peaks at 3.6, 7.1, 12.3, 12.8, and 16.7 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the besylate salt of Compound 1, Form II, is characterized by substantially conforming to Figure 6 X-ray powder diffraction pattern of .

[0103] Differential scanning calorimetry (DSC) can also be used to characterize the benzenesulfonate salt form II of compound 1 described herein. In some embodiments, the benzenesulfonate salt form II of compound 1 is characterized in that the differential scanning calorimetry thermogram (DSC) includes an endothermic peak at about 187.2°C. In some embodiments, the benzenesulfonate salt form II of compound 1 is characterized in that the melting point starts at about 180.5°C as determined by the differential scanning calorimetry thermogram (DSC). In some embodiments, the benzenesulfonate salt form II of compound 1 is characterized in that it is substantially the same as Figure 7 Consistent Differential Scanning Calorimetry (DSC) thermograms.

[0104] Thermogravimetric analysis (TGA) is another technique that can be used to characterize the benzenesulfonate salt Form II of Compound 1 described herein. In some embodiments, Form II of the benzenesulfonate salt of Compound 1 is characterized by a weight loss of about 0.095% when heated to about 189.5° C. as measured by thermogravimetric analysis (TGA). In some embodiments, Form II of the benzenesulfonate salt of Compound 1 is characterized by substantially conforming to Figure 7 Thermogravimetric analysis (TGA) thermogram.

[0105] iii. Tosylate of Compound 1 (Form I)

[0106] In some aspects, the present invention provides a tosylate salt of Compound 1, Form I

[0107]

[0108] It is substantially free of other crystalline or amorphous forms of Compound 1.

[0109] In some embodiments, the tosylate salt Form I of Compound 1 is characterized in that an X-ray powder diffraction pattern includes peaks at 7.6, 10.8, 13.1, 16.5, 19.7, 21.6 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the tosylate salt Form I of Compound 1 is further characterized in that an X-ray powder diffraction pattern includes peaks at 6.6, 15.3, 16.0, and 27.8 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the tosylate salt Form I of Compound 1 is characterized in that an X-ray powder diffraction pattern is substantially the same as Figure 8 Consistent.

[0110] Differential scanning calorimetry (DSC) can also be used to characterize the tosylate salt Form I of Compound 1 described herein. In some embodiments, the tosylate salt Form I of Compound 1 is characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at about 209.8°C. In some embodiments, the tosylate salt Form I of Compound 1 is characterized by a melting point onset of about 206.1°C as determined by a differential scanning calorimetry thermogram (DSC). In some embodiments, the tosylate salt Form I of Compound 1 is characterized by a differential scanning calorimetry (DSC) thermogram substantially consistent with Fig. 9 .

[0111] Thermogravimetric analysis (TGA) is another technique that can be used to characterize Form I of the tosylate salt of Compound 1 described herein. In some embodiments, Form I of the tosylate salt of Compound 1 is characterized by a weight loss of about 0.19% when heated to about 204.2° C. as measured by thermogravimetric analysis (TGA). In some embodiments, Form I of the tosylate salt of Compound 1 is characterized by substantially conforming to Fig. 9 Thermogravimetric analysis (TGA) thermogram.

[0112] Dynamic vapor sorption (DVS) is another method that can be used to characterize the crystalline form I of the tosylate salt of compound 1 described herein. In some embodiments, the crystalline form I of the tosylate salt of compound 1 is characterized by a weight gain of about 0.58% after undergoing a dynamic vapor sorption cycle (DVS) from about 0% relative humidity (RH) to about 75% relative humidity at 25°C. In some embodiments, the crystalline form I of the tosylate salt of compound 1 is characterized by a weight gain of about 0.83% after undergoing a dynamic vapor sorption cycle (DVS) from about 5% relative humidity (RH) to about 95% relative humidity at 25°C. In some embodiments, the crystalline form I of the tosylate salt of compound 1 is characterized by substantially conforming to Fig.10 Dynamic vapor sorption (DVS) diagram.

[0113] Microscopy can also be used to characterize the Form I tosylate salt of Compound 1 described herein. In some embodiments, a scanning electron microscope (SEM) is used. In some embodiments, Form I tosylate salt of Compound 1 is characterized by having an SEM image of mainly blade-shaped, rod-shaped, or isodiameter particles. In some embodiments, the particles are about 1 μm to 500 μm as measured by SEM. In some embodiments, Form I tosylate salt of Compound 1 is characterized by substantially conforming to Fig.11 Scanning electron microscope (SEM) image of the .

[0114] Polarized light microscopy (PLM) is another technique that can be used to characterize the crystalline tosylate salt of Compound 1 described herein, Form I. In some embodiments, the crystalline tosylate salt of Compound 1, Form I, is characterized by particles having a size range of about 2.5 to 440 μm as determined by polarized light microscopy (PLM). In some embodiments, the crystalline tosylate salt of Compound 1, Form I, is characterized by particles having a size range of about 2.5 to 440 μm as determined by polarized light microscopy (PLM). Fig.12 Polarized light microscopy (PLM) profile shown.

[0115] iv. Naphthalene disulfonate salt of compound 1 (crystalline form I)

[0116] In some aspects, the present invention provides a naphthalene disulfonate salt of compound 1, Form I

[0117]

[0118] It is substantially free of other crystalline or amorphous forms of Compound 1.

[0119] In some embodiments, the naphthalene disulfonate salt of Compound 1, Form I, is characterized in that an X-ray powder diffraction pattern includes peaks at 6.5, 7.0, 12.4, 14.7, 15.2, and 18.0 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the naphthalene disulfonate salt of Compound 1, Form I, is further characterized in that an X-ray powder diffraction pattern includes peaks at 9.6, 11.2, 18.6, and 20.4 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the naphthalene disulfonate salt of Compound 1, Form I, is characterized in that an X-ray powder diffraction pattern substantially conforms to Fig.13 .

[0120] Differential scanning calorimetry (DSC) can also be used to characterize the naphthalene disulfonate salt Form I of Compound 1 described herein. In some embodiments, the naphthalene disulfonate salt Form I of Compound 1 is characterized in that the differential scanning calorimetry thermogram (DSC) includes an endothermic peak at about 232.8°C. In some embodiments, the naphthalene disulfonate salt Form I of Compound 1 is characterized in that the melting point starts at about 222.7°C as determined by the differential scanning calorimetry thermogram (DSC). In some embodiments, the naphthalene disulfonate salt Form I of Compound 1 is characterized in that the differential scanning calorimetry (DSC) thermogram substantially conforms to Fig.14 .

[0121] Thermogravimetric analysis (TGA) is another technique that can be used to characterize the naphthalene disulfonate salt of Compound 1 described herein, Form I. In some embodiments, Form I of the naphthalene disulfonate salt of Compound 1 is characterized by a weight loss of about 2.0% when heated to about 233.1° C. as measured by thermogravimetric analysis (TGA). In some embodiments, Form I of the naphthalene disulfonate salt of Compound 1 is characterized by substantially conforming to Fig.14 Thermogravimetric analysis (TGA) thermogram.

[0122] Dynamic vapor sorption (DVS) is another method that can be used to characterize the naphthalene disulfonate salt of compound 1, Form I, described herein. In some embodiments, the naphthalene disulfonate salt of compound 1, Form I, is characterized by a weight gain of about 0.6% after undergoing a dynamic vapor sorption cycle (DVS) from about 0% relative humidity (RH) to about 55% relative humidity at 25°C. In some embodiments, the naphthalene disulfonate salt of compound 1, Form I, is characterized by a weight gain of about 1.42% after undergoing a dynamic vapor sorption cycle (DVS) from about 5% relative humidity (RH) to about 95% relative humidity at 25°C. In some embodiments, the naphthalene disulfonate salt of compound 1, Form I, is characterized by substantially meeting Fig.15 Dynamic vapor sorption (DVS) diagram.

[0123] Microscopy can also be used to characterize the naphthalene disulfonate salt Form I of Compound 1 described herein. In some embodiments, a scanning electron microscope (SEM) is used. In some embodiments, the naphthalene disulfonate salt Form I of Compound 1 is characterized in that the SEM image mainly has blade-shaped, rod-shaped or isodiameter particles. In some embodiments, the particles are about 1 μm to 150 μm as measured by SEM. In some embodiments, the naphthalene disulfonate salt Form I of Compound 1 is characterized in that it substantially meets Fig.16 Scanning electron microscope (SEM) image of the .

[0124] Polarized light microscopy (PLM) is another technique that can be used to characterize the naphthalene disulfonate salt of Compound 1, Form I, described herein. In some embodiments, the naphthalene disulfonate salt of Compound 1, Form I, is characterized by particles having a size range of about 1.3 to 75 μm as measured by polarized light microscopy (PLM). In some embodiments, the naphthalene disulfonate salt of Compound 1, Form I, is characterized by particles having a size range of about 1.3 to 75 μm as measured by polarized light microscopy (PLM). Fig.17 Polarized light microscopy (PLM) profile shown.

[0125] v. Naphthalenesulfonate salt of compound 1 (crystalline form I)

[0126] In some aspects, the present invention provides a naphthalenesulfonate salt of compound 1, Form I

[0127]

[0128] It is substantially free of other crystalline or amorphous forms of Compound 1.

[0129] In some embodiments, the naphthalenesulfonate salt of Compound 1, Form I, is characterized by an X-ray powder diffraction pattern including peaks at 6.5, 7.7, 10.4, 12.9, and 16.1 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the naphthalenesulfonate salt of Compound 1, Form I, is further characterized by an X-ray powder diffraction pattern including peaks at 15.4, 15.5, 17.8, and 20.8 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the naphthalenesulfonate salt of Compound 1, Form I, is characterized by an X-ray powder diffraction pattern substantially similar to Fig.18 Consistent.

[0130] Differential scanning calorimetry (DSC) can also be used to characterize the naphthalenesulfonate salt of compound 1, Form I, described herein. In some embodiments, the naphthalenesulfonate salt of compound 1, Form I, is characterized in that a differential scanning calorimetry thermogram (DSC) includes an endothermic peak at about 218.3°C. In some embodiments, the naphthalenesulfonate salt of compound 1, Form I, is characterized in that a melting point onset of about 211.7°C as determined by a differential scanning calorimetry thermogram (DSC). In some embodiments, the naphthalenesulfonate salt of compound 1, Form I, is characterized in that a differential scanning calorimetry (DSC) thermogram substantially conforms to Fig.19 .

[0131] Thermogravimetric analysis (TGA) is another technique that can be used to characterize the naphthalenesulfonate salt Form I of Compound 1 described herein. In some embodiments, the naphthalenesulfonate salt Form I of Compound 1 is characterized by a weight loss of about 0.49% when heated to about 217° C. as measured by thermogravimetric analysis (TGA). In some embodiments, the naphthalenesulfonate salt Form I of Compound 1 is characterized by substantially conforming to Fig.19Thermogravimetric analysis (TGA) thermogram.

[0132] Dynamic vapor sorption (DVS) is an additional method that can be used to characterize the naphthalenesulfonate salt of compound 1, Form I, described herein. In some embodiments, the naphthalenesulfonate salt of compound 1, Form I, is characterized by a weight gain of about 0.2% after undergoing a dynamic vapor sorption cycle (DVS) from about 0% relative humidity (RH) to about 55% relative humidity at 25°C. In some embodiments, the naphthalenesulfonate salt of compound 1, Form I, is characterized by a weight gain of about 0.65% after undergoing a dynamic vapor sorption cycle (DVS) from about 5% relative humidity (RH) to about 95% relative humidity at 25°C. In some embodiments, the naphthalenesulfonate salt of compound 1, Form I, is characterized by substantially meeting Fig. 20 Dynamic vapor sorption (DVS) diagram.

[0133] Microscopy can also be used to characterize the naphthalenesulfonate salt Form I of Compound 1 described herein. In some embodiments, a scanning electron microscope (SEM) is used. In some embodiments, the naphthalenesulfonate salt Form I of Compound 1 is characterized by having SEM images of mainly blades, rods, and equal amounts of particles. In some embodiments, the particles are about 1 μm to 150 μm as determined by SEM. In some embodiments, the naphthalenesulfonate salt Form I of Compound 1 is characterized by being substantially based on Fig.21 Scanning electron microscope (SEM) image of the .

[0134] Polarized light microscopy (PLM) is another technique that can be used to characterize the naphthalenesulfonate salt of Compound 1, Form I, described herein. In some embodiments, the naphthalenesulfonate salt of Compound 1, Form I, is characterized by particles having a size range of about 5 to 470 μm as measured by polarized light microscopy (PLM). In some embodiments, the naphthalenesulfonate salt of Compound 1, Form I, is characterized by particles having a size range of about 5 to 470 μm as measured by polarized light microscopy (PLM). Fig. 22 Polarized light microscopy (PLM) profile shown.

[0135] vi. Camphorsulfonate of Compound 1 (Form I)

[0136] In some aspects, the present invention provides a camphorsulfonate salt of compound 1, Form I

[0137]

[0138] It is substantially free of other crystalline or amorphous forms of Compound 1.

[0139] In some embodiments, the camsylate salt of Compound 1, Form I, is characterized by an X-ray powder diffraction pattern comprising peaks at 6.3, 7.9, 10.8, 12.2, and 16.1 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the camsylate salt of Compound 1, Form I, is further characterized by an X-ray powder diffraction pattern comprising peaks at 7.4, 8.5, 13.6, 17.0, and 18.5 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the camsylate salt of Compound 1, Form I, is characterized by an X-ray powder diffraction pattern substantially similar to Fig.23 Consistent.

[0140] Differential scanning calorimetry (DSC) can also be used to characterize the camsylate salt of Compound 1, Form I, described herein. In some embodiments, the camsylate salt of Compound 1, Form I, is characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at about 209.8°C. In some embodiments, the camsylate salt of Compound 1, Form I, is characterized by a melting point onset of about 202.8°C as determined by a differential scanning calorimetry thermogram (DSC). In some embodiments, the camsylate salt of Compound 1, Form I, is characterized by a differential scanning calorimetry (DSC) thermogram substantially similar to Fig.24 Consistent.

[0141] Thermogravimetric analysis (TGA) is another technique that can be used to characterize the crystalline Form I of the camphorsulfonate salt of Compound 1 described herein. In some embodiments, the crystalline Form I of the camphorsulfonate salt of Compound 1 is characterized by a weight loss of about 0.23% when heated to about 205.0° C. as measured by thermogravimetric analysis (TGA). In some embodiments, the crystalline Form I of the camphorsulfonate salt of Compound 1 is characterized by substantially conforming to Fig.24 Thermogravimetric analysis (TGA) thermogram.

[0142] Dynamic vapor sorption (DVS) is another method that can be used to characterize the camsylate salt of compound 1, Form I, described herein. In some embodiments, the camsylate salt of compound 1, Form I, is characterized by a weight gain of about 0.35% after undergoing a dynamic vapor sorption cycle (DVS) from about 0% relative humidity (RH) to about 65% relative humidity at 25°C. In some embodiments, the camsylate salt of compound 1, Form I, is characterized by a weight gain of about 0.96% after undergoing a dynamic vapor sorption cycle (DVS) from about 5% relative humidity (RH) to about 95% relative humidity at 25°C. In some embodiments, the camsylate salt of compound 1, Form I, is characterized by substantially meeting Fig.25 Dynamic vapor sorption (DVS) diagram.

[0143] Microscopy can also be used to characterize the camphorsulfonate salt Form I of Compound 1 described herein. In some embodiments, a scanning electron microscope (SEM) is used. In some embodiments, the camphorsulfonate salt Form I of Compound 1 is characterized in that the SEM image mainly has flat-ended blade-shaped and rod-shaped particles. In some embodiments, the particles are about <1 μm to 77 μm as determined by SEM. In some embodiments, the camphorsulfonate salt Form I of Compound 1 is characterized in that it substantially meets Fig.26 Scanning electron microscope (SEM) image of the .

[0144] Polarized light microscopy (PLM) is another technique that can be used to characterize the camsylate salt Form I of Compound 1 described herein. In some embodiments, the camsylate salt Form I of Compound 1 is characterized by particles having a size range of about 2.5 to 84 μm as determined by polarized light microscopy (PLM). In some embodiments, the camsylate salt Form I of Compound 1 is characterized by particles having a size range of about 2.5 to 84 μm as determined by polarized light microscopy (PLM). Fig. 27 Polarized light microscopy (PLM) profile shown.

[0145] vii. Ethylenedisulfonate of Compound 1 (Form I)

[0146] In some aspects, the present invention provides a crystalline form I of the edisylate salt of compound 1

[0147]

[0148] It is substantially free of other crystalline or amorphous forms of Compound 1.

[0149] In some embodiments, the edisylate salt of Compound 1, Form I, is characterized in that an X-ray powder diffraction pattern includes peaks at 3.4, 5.6, 12.9, 15.3, 18.1, and 20.8 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the edisylate salt of Compound 1, Form I, is further characterized in that an X-ray powder diffraction pattern includes peaks at 7.3, 10.7, 14.5, 15.6, 19.1, and 19.7 degrees 2θ (±0.2 degrees 2θ). In some embodiments, the edisylate salt of Compound 1, Form I, is characterized in that an X-ray powder diffraction pattern is substantially the same as Fig.28 Consistent.

[0150] Differential scanning calorimetry (DSC) can also be used to characterize the edisylate salt Form I of Compound 1 described herein. In some embodiments, the edisylate salt Form I of Compound 1 is characterized in that the differential scanning calorimetry thermogram (DSC) includes an endothermic peak at about 213.3°C. In some embodiments, the edisylate salt Form I of Compound 1 is characterized in that the melting point starts at about 205.2°C as determined by the differential scanning calorimetry thermogram (DSC). In some embodiments, the edisylate salt Form I of Compound 1 is characterized in that the differential scanning calorimetry (DSC) thermogram substantially meets Fig.29 .

[0151] B. Pharmaceutical Compositions

[0152] The present invention provides a pharmaceutical composition comprising a salt form of Compound 1 described herein or a liquid pharmaceutical composition prepared using a salt form of Compound 1 described herein. The pharmaceutical composition will include one or more pharmaceutically acceptable excipients.

[0153] Pharmaceutical compositions containing the salt form of Compound 1 described in the present invention can be in a form suitable for oral use, such as tablets, troches, lozenges, liquid preparations, aqueous or oily suspensions, dispersible powders or granules, emulsions and self-emulsifiers (such as described in U.S. Patent Application 2002-0012680), hard or soft capsules, syrups, elixirs, solutions, oral patches, oral gels, chewing gums, chewable tablets, effervescent powders and effervescent tablets. Compositions intended for oral administration can be prepared according to any method known in the art for preparing pharmaceutical compositions, and the composition may contain one or more agents selected from sweeteners, flavoring agents, coloring agents, antioxidants and preservatives to provide pharmaceutically elegant and palatable preparations.

[0154] Tablets contain a salt form of Compound 1 mixed with non-toxic pharmaceutically acceptable excipients suitable for the manufacture of tablets. These excipients may be, for example, inert diluents such as cellulose, silicon dioxide, aluminum oxide, calcium carbonate, sodium carbonate, glucose, mannitol, sorbitol, lactose, calcium phosphate or sodium phosphate; granulating and disintegrants such as corn starch or alginic acid; binders such as PVP, cellulose, PEG, starch, gelatin or acacia, and lubricants such as magnesium stearate, stearic acid or talc.

[0155] Tablets may be uncoated or may be enteric or otherwise coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over a longer period of time. For example, time-delay materials such as glyceryl monostearate or glyceryl distearate may be used. They may also be coated by the techniques described in U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for controlled release.

[0156] Oral preparations can also be provided in the form of hard gelatin capsules, wherein the salt form of Compound 1 is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin; or in the form of soft gelatin capsules, wherein the salt form of Compound 1 is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil. In addition, emulsions can be prepared with water-immiscible ingredients, such as oils; and stabilized with surfactants, such as mono-diglycerides, PEG esters, and the like.

[0157] Aqueous suspensions for oral administration contain a salt form of Compound 1 mixed with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum arabic; dispersants or wetting agents can be naturally occurring phospholipids such as lecithin, or condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain fatty alcohols, such as heptadecaethyleneoxyhexadecanoate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides such as polysorbitol monooleate and other poloxamers (e.g., poloxamer F-68). The aqueous suspension may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0158] Thus, the present invention provides an aqueous suspension comprising a salt form of Compound 1 and at least one excipient. In some embodiments, the at least one excipient is at least one suspending agent and / or at least one wetting agent as described above.

[0159] Oily suspensions for oral use can be prepared by suspending the salt form of Compound 1 in a vegetable oil such as peanut oil, olive oil, sesame oil or coconut oil, or a mineral oil such as liquid paraffin. Oily suspensions can contain thickeners such as beeswax, hard paraffin or cetyl alcohol. Sweeteners and flavorings such as those described above can be added to provide a palatable oral preparation. These compositions can be preserved by adding antioxidants such as ascorbic acid.

[0160] The pharmaceutical composition can be in the form of a sterile injectable or infusible aqueous or oily solution or suspension. The solution or suspension can be prepared according to known techniques using those suitable dispersants or wetting agents and suspending agents mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.

[0161] Acceptable carriers and solvents that can be used include water, Ringer's solution, isotonic sodium chloride solution, isotonic aqueous buffer solution, and saline, disintegrants such as PEG (e.g., PEG200, PEG400, PEG800, etc.) and nonionic surfactants such as Tween 80. In addition, sterile fixed oils are generally used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can be used to prepare injections and infusions. Compositions for injectable or infusible administration optionally include local anesthetics, such as lidocaine, to relieve pain at the injection site. The ingredients can be pre-mixed or provided separately, and the ingredients are mixed shortly before use. In some embodiments, it is necessary to mix shortly before use to utilize the high initial solubility of the salt form of compound 1 described herein in certain liquid formulation mixtures.

[0162] Injectable or infusible compositions include, but are not limited to, intravenous administration, intramuscular administration, and subcutaneous or intrasternal injection. Therefore, in some embodiments, the present invention provides an injectable or infusible solution comprising compound 1 and at least one wetting agent or solvent, wherein the intravenous pharmaceutical composition is prepared using the salt form of compound 1 described in the present invention. In some embodiments, the injectable or infusible solution is prepared for intravenous administration. In some embodiments, the injectable or infusible solution is prepared for intramuscular administration. In some embodiments, the injectable or infusible solution is prepared for subcutaneous injection. In some embodiments, the injectable or infusible solution is prepared for intrasternal injection. In some embodiments, at least one wetting agent or solvent in the injectable or infusible pharmaceutical composition includes saline, a disintegrant, and a nonionic surfactant.

[0163] The injectable or infusible composition can be prepared at any time convenient to the physician or user; this includes shortly before use or well in advance of use. In some embodiments, the composition is prepared shortly before use. Shortly before use includes 0-24 hours before use, 0-10 hours before use, 0-5 hours before use, or 0-1 hour before use. In some embodiments, the injectable or infusible composition is prepared 0-5 hours before use. Well in advance of use generally refers to one or more days before use. Therefore, the present invention also provides a method for preparing an injectable or infusible solution. The method includes dissolving a salt form of compound 1 with at least one wetting agent or solvent to prepare an injectable or infusible solution; and administering the injectable or infusible solution to a subject in need.

[0164] Dispersible powders and granules suitable for preparing aqueous oral preparations or oral suspensions by adding water provide a salt form of compound 1 mixed with a dispersant or wetting agent, a suspending agent and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are, for example, those already mentioned above. Other excipients, such as sweeteners, flavoring agents and coloring agents, may also be present.

[0165] Pharmaceutical compositions of the present invention can also be in the form of water-in-oil emulsions. The oil phase can be a vegetable oil, such as olive oil or peanut oil, or a mineral oil, such as liquid paraffin or a mixture of these. Suitable emulsifiers can be naturally occurring gums, such as gum arabic or tragacanth, naturally occurring phospholipids, such as soybeans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and products of condensation of the partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion can also contain sweeteners and flavorings.

[0166] Syrups and elixirs can be formulated with sweeteners, such as glycerol, propylene glycol, sorbitol or sucrose. Such preparations may also contain demulcents, preservatives, and flavoring and coloring agents. Oral solutions may be prepared in combination with, for example, cyclodextrins, PEG and surfactants.

[0167] The compounds of the present invention can also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing the salt form of compound 1 with a suitable non-irritating excipient, which is solid at room temperature but liquid at rectal temperature, and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycol. In addition, the compound can be administered by ocular delivery in the form of a solution or ointment. Further, transdermal delivery of the subject compound can be achieved by iontophoresis patches, etc. For topical use, creams, ointments, gels, solutions or suspensions containing the compounds of the present invention are used. As used in the present invention, topical application also means including the use of mouthwashes and gargles.

[0168] Compound of the present invention can also be coupled with a carrier as a suitable polymer of a targetable drug carrier. Such polymers can include polyvinylpyrrolidone, pyran copolymers, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-asparagine-phenol, or polyethylene oxide-polylysine substituted by palmitoyl residues. In addition, compound of the present invention can be coupled with a carrier, which is a class of biodegradable polymers that can be used to realize controlled release of drugs, such as crosslinking of polylactic acid, polyglycolic acid, polylactic acid and polyglycolic acid copolymers, polycaprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and hydrogels, or amphiphilic block copolymers. Polymer and semipermeable polymer matrix can form shaped articles, such as valves, stents, pipes, prostheses, etc. In one embodiment of the invention, compound of the present invention is coupled with a polymer or semipermeable polymer matrix formed as stent or stent graft device.

[0169] C. Treatment methods

[0170] The invention also provides methods of treating an individual suffering from a disorder responsive to C5a receptor modulation.

[0171] In some aspects, the present invention provides a method of treating an individual suffering from or susceptible to a disease or condition involving pathological activation of the C5a receptor, comprising administering to the individual an effective amount of a salt form of Compound 1 or a pharmaceutical formulation comprising Compound 1 described herein.

[0172] In some embodiments, the salt form of Compound 1 described herein is used to treat a patient suffering from a disorder responsive to C5a receptor modulation.

[0173] Conditions that can be treated with C5a modulation:

[0174] Autoimmune diseases - For example, rheumatoid arthritis, systemic lupus erythematosus, Guillain-Barré syndrome, pancreatitis, C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), lupus nephritis, lupus glomerulonephritis, immunoglobulin A (IgA) nephropathy, psoriasis, Crohn's disease, vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolysis and thrombocytopenia, Goodpasture's syndrome (and related glomerulonephritis and pulmonary hemorrhage), immune vasculitis, tissue transplant rejection, hyperacute rejection of transplanted organs; and the like.

[0175] Inflammatory diseases and related conditions- For example, neutropenia, sepsis, septic shock, Alzheimer's disease, multiple sclerosis, stroke, inflammatory bowel disease (IBD), age-related macular degeneration (AMD, wet and dry forms), inflammation associated with severe burns, lung injury and ischemia-reperfusion injury, osteoarthritis, as well as acute (adult) respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), systemic inflammatory response syndrome (SIRS), atopic dermatitis, psoriasis, chronic urticaria, and multiple organ dysfunction syndrome (MODS). Also included are pathological sequelae associated with: insulin-dependent diabetes (including diabetic retinopathy), lupus nephropathy, Heimann nephritis, membranous nephritis and other forms of glomerulonephritis, contact sensitivity reactions, and inflammation caused by contact of blood with artificial surfaces that can cause complement activation, such as during extracorporeal circulation of blood (e.g., during hemodialysis or through, for example, a heart-lung machine associated with vascular surgery such as coronary artery bypass grafting or heart valve replacement), or with other artificial blood vessels or container surfaces (e.g., ventricular assist devices, artificial heart machines, infusion tubes, blood storage bags, plasmapheresis, platelet exchange, etc.). Also included are diseases associated with ischemia / reperfusion injury, such as diseases caused by transplantation, including solid organ transplantation, and syndromes such as ischemia-reperfusion injury, ischemic colitis, and cardiac ischemia. The salt form of compound 1 described in the present invention can also be used to treat age-related macular degeneration (Hageman et al., Proceedings of the National Academy of Sciences of the United States of America. 102:7227-7232, 2005).

[0176] Cardiovascular and cerebrovascular diseases ——For example, myocardial infarction, coronary thrombosis, vascular occlusion, postoperative vascular reocclusion, atherosclerosis, traumatic central nervous system injury and ischemic heart disease. In one embodiment, an effective amount of the salt form of compound 1 described in the present invention can be administered to patients at risk of myocardial infarction or thrombosis (i.e., patients with one or more recognized risk factors for myocardial infarction or thrombosis, such as but not limited to obesity, smoking, hypertension, hypercholesterolemia, a history of myocardial infarction or thrombosis or a genetic history) to reduce the risk of myocardial infarction or thrombosis.

[0177] Vasculitis——Vasculitis diseases are characterized by inflammation of blood vessels. The infiltration of leukocytes leads to the destruction of the vascular wall, and the complement pathway is believed to play a major role in initiating leukocyte migration and the resulting damage manifested at the site of inflammation (Vasculitis, Second Edition, edited by Ball and Bridges, Oxford University Press, pp. 47-53, 2008). The salt form of compound 1 described in the present invention can be used to treat vasculitis, including anti-neutrophil cytoplasmic antibody-associated vasculitis (or ANCA-associated vasculitis, which includes microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis, also known as Wegener's disease), Chag-Strauss syndrome, Henoch-Schönlein purpura, polyarteritis nodosa, rapidly progressive glomerulonephritis (RPGN), cryoglobulinemia, giant cell arteritis (GCA), Behcet's disease and Takayasu's arteritis (TAK).

[0178] HIV infection and AIDS ——The salt form of compound 1 of the present invention can be used to inhibit HIV infection, delay the progression of AIDS or reduce the symptoms or severity of HIV infection and AIDS

[0179] Neurodegenerative and related diseases - In a further embodiment, the salt forms of Compound 1 described herein are useful for treating Alzheimer's disease, multiple sclerosis, and cognitive decline associated with cardiopulmonary bypass surgery and related procedures.

[0180] cancer ——The salt form of compound 1 described in the present invention can also be used to treat cancer and precancerous lesions in subjects. Specific cancers that can be treated include, but are not limited to, sarcomas, carcinomas, and mixed tumors. Exemplary conditions that can be treated according to the present invention include fibrosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, angiosarcoma, lymphangiosarcoma, synovioma, mesothelioma, meningioma, leukemia, lymphoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, melanoma, renal cell carcinoma, hepatocellular carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, pleomorphic adenoma, hepatocellular papilloma, renal tubular adenoma, cystadenoma, papilloma, adenoma, leiomyoma, rhabdomyomas, hemangiomas, lymphangiomas, osteomas, chondromas, lipomas, and fibromas.

[0181] In some embodiments, the salt form of Compound 1 described herein can be used to treat a disease selected from the group consisting of sepsis (and related disorders), COPD, rheumatoid arthritis, lupus nephritis, and multiple sclerosis.

[0182] In some embodiments, the salt form of Compound 1 described herein can be used to treat a disease selected from the group consisting of anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis, C3 glomerulopathy, hidradenitis suppurativa, and lupus nephritis.

[0183] The treatment methods provided herein generally comprise administering to a patient an effective amount of a salt form of Compound 1. Suitable patients include those suffering from or susceptible to (i.e., prophylactic treatment) the conditions or diseases identified by the present invention. Typical patients for the treatment described herein include mammals, particularly primates, and especially humans. Other suitable patients include domesticated companion animals such as dogs, cats, horses, etc., or livestock such as cattle, pigs, sheep, etc.

[0184] In general, the treatment methods provided by the present invention include administering to the patient an effective amount of a salt form of the compound 1 of the present invention. The exact formulation, route of administration and dosage of the pharmaceutical composition of the present invention can be selected by an individual physician according to the patient's condition. (See, for example, Fingl et al. 1975, in "Pharmacological Basis of Therapeutics", which is incorporated herein by reference as a whole, particularly with reference to Chapter 1, page 1). In some embodiments, the salt form of the compound 1 of the present invention is orally administered to a patient (e.g., a human). In some embodiments, the salt form of the compound 1 of the present invention is administered to a patient (e.g., a human) intravenously, intramuscularly, or by subcutaneous or intrasternal injection. An effective amount can be an amount sufficient to modulate the activity of the C5a receptor and / or an amount sufficient to alleviate or reduce the symptoms presented by the patient. Preferably, the amount administered is sufficient to produce a sufficiently high plasma concentration of the compound (or its active metabolite, if the compound is a prodrug) to detectably inhibit leukocyte (e.g., neutrophil) chemotaxis in vitro.

[0185] For treating most diseases by oral administration, a person skilled in the art can determine a suitable frequency of administration. In some embodiments, a frequency of administration of 4 times a day or less is preferred. In some embodiments, a dosage regimen of 2 times a day is used. In some embodiments, administration is used once a day. The salt form of compound 1 can be administered to the patient in a fed or fasting state. In some embodiments, the patient takes the salt form of compound 1 with food. In some embodiments, the patient takes the salt form of compound 1 without food.

[0186] For treating most diseases by intravenous, intramuscular administration or by subcutaneous or intrasternal injection, a person skilled in the art can determine a suitable dosing frequency. In some embodiments, the dosing frequency is about once every two weeks. In some embodiments, the dosing frequency is about once a week. In some embodiments, the dosing frequency is about 3 times a week. In some embodiments, the dosing frequency is about 2 to 5 times a week. In some embodiments, the dosing frequency is about once every other day. In some embodiments, the dosing frequency is about once a day.

[0187] However, it should be understood that the specific dosage level and treatment regimen for any particular patient will depend on a variety of factors, including age, body weight, general health, sex, diet, administration time, administration route, excretion rate, drug combination (i.e., other drugs given to the patient) and the severity of the specific disease being treated, as well as the judgment of the prescribing practitioner. Generally, it is preferred to use the minimum dose sufficient to provide effective treatment. Medical or veterinary standards suitable for the condition being treated or prevented can usually be used to monitor the therapeutic effect of the patient.

[0188] Dosage levels of the order of about 0.1 mg to about 140 mg per kilogram of body weight per day can be used to treat or prevent conditions involving pathogenic C5a activity (about 0.5 mg to about 7 g per person per day). The amount of salt form of Compound 1 that can be combined with a carrier material to produce a single dosage form will vary depending on the host being treated and the specific mode of administration. The dosage unit form typically contains about 1 mg to about 500 mg of the salt form of Compound 1. When administered orally, transdermally, intravenously or subcutaneously, it is preferred to administer a sufficient amount of the salt form of the compound 1 to achieve a serum concentration of 5 ng (nanograms) / mL-10 μg (micrograms) / mL serum, more preferably sufficient compound should be administered to achieve a serum concentration of 20 ng-1 μg / ml serum, and most preferably sufficient compound should be administered to achieve a serum concentration of 50 ng / ml-200 ng / ml serum. For direct injection into the synovium (for the treatment of arthritis), a sufficient amount of the salt form of Compound 1 should be administered to achieve a local concentration of about 1 micromolar.

[0189] D. Combination therapy

[0190] The methods disclosed herein may include combined therapy with one or more additional therapeutic agents for treating, preventing, inhibiting or ameliorating diseases or conditions involving pathological activation of C5a receptors. Such one or more additional therapeutic agents may be administered simultaneously or sequentially with the salt form of compound 1 described herein by routes and amounts commonly used therefor. When the salt form of compound 1 described herein is used simultaneously with an additional therapeutic agent, a pharmaceutical composition containing such other drugs in addition to the salt form of compound 1 is preferred. Therefore, the pharmaceutical compositions of the present invention include compositions containing one or more other active ingredients or therapeutic agents in addition to the salt form of compound 1 described herein.

[0191] Examples of the one or more additional therapeutic agents are corticosteroids, steroids, immunosuppressants, immunoglobulin G agonists, dipeptidyl peptidase IV inhibitors, lymphocyte function antigen-3 receptor antagonists, interleukin-2 ligands, interleukin-1β ligand inhibitors, IL-2 receptor α subunit inhibitors, HGF gene stimulators, IL-6 antagonists, IL-5 antagonists, α1 antitrypsin stimulators, histone deacetylase inhibitors, AKT protein kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase inhibitors, JAK tyrosine kinase inhibitors, TNFα ligand inhibitors, hemoglobin regulators, TNF antagonists, proteasome inhibitors, CD3 regulators, Hsp70 family inhibitors, immunoglobulin agonists, CD30 antagonists, tubulin antagonists, sphingosine 1-phosphate receptor 1 agonists, connective tissue growth factor ligand inhibitors, caspase inhibitors, adrenocorticotropic hormone ligands, Btk tyrosine kinase inhibitors, complement C1s subcomponents inhibitors, erythropoietin receptor agonists, B lymphocyte stimulator ligand inhibitors, cyclin-dependent kinase 2 inhibitors, P-selectin glycoprotein ligand 1 stimulators, mTOR inhibitors, elongation factor 2 inhibitors, cell adhesion molecule inhibitors, factor XIII agonists, calcineurin inhibitors, immunoglobulin G1 agonists, inosine monophosphate dehydrogenase inhibitors, complement C1s subcomponent inhibitors, thymidine kinase modulators, cytotoxic T-lymphocyte protein 4 modulators, angiotensin II receptor antagonists, angiotensin II receptor modulators, TNF superfamily receptor 12A antagonists, CD52 antagonists, adenosine deaminase inhibitors, T-cell differentiation antigen CD6 inhibitors, FGF-7 ligands, dihydroorotate dehydrogenase inhibitors, Syk tyrosine kinase inhibitors, type I interferon receptor antagonists, interferon alpha ligand inhibitors, macrophage migration inhibitory factor inhibitors, integrin alpha-V / beta-6 antagonists, cysteine ​​protease stimulators, p38MAP kinase inhibitors, TP53 gene inhibitors, Shiga-like toxin I inhibitors, fucosyltransferase 6 stimulators, interleukin 22 ligands, IRS1 gene inhibitors, protein kinase C stimulators, protein kinase Cα inhibitors, CD74 antagonists, immunoglobulin gamma Fc receptor IIB antagonists, T cell antigen CD7 inhibitors, CD95 antagonists, N-acetyl mannosamine kinase stimulators, cardiotrophin-1 ligands, leukocyte elastase inhibitors, CD40 ligand receptor antagonists, CD40 ligand modulators, IL-17 antagonists, TLR-2 antagonists, mannan-binding lectin serine protease 2 (MASP-2) inhibitors, factor B inhibitors Agents, factor D inhibitors, C3aR modulators, C5aR2 modulators, T cell receptor antagonists, PD-1 inhibitors, PD-L1 inhibitors, TIGIT inhibitors, TIM-3 inhibitors, LAG-3 inhibitors, VISTA inhibitors, STING agonists, IDO inhibitors, adenosine receptor modulators, CD39 inhibitors, CD73 inhibitors, chemokine receptor (especially CXCR1, CXCR2, CXCR3, CXCR4, CXCR7, CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR7, CCR9, CX3CR1 and CXCR6) antagonists, and combinations thereof.

[0192] In some embodiments, the additional therapeutic agent used in the treatment methods of the present invention is selected from the group consisting of obinutuzumab, rituximab, ocrelizumab, tositumomab, obinutuzumab, ibritumomab, cyclophosphamide, prednisone, hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortolone pivalate, prednisolone, methylprednisolone, triamcinolone acetonide, triamcinolone acetonide alcohol, mometasone, amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinolone acetonide, halcinonide, betamethasone, betamethasone sodium phosphate, dexamethasone , dexamethasone sodium phosphate, flucortolone, hydrocortisone-17-valerate, halometasone, alclometasone dipropionate, beclomethasone, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, flucortolone caproate, flucortolone valproate, fluprednidine acetate, hydrocortisone-17-butyrate, hydrocortisone-17-propyl acetate, hydrocortisone-17-butyl acetate, ciclesonide and prednicarbate, GB-0998, immunoglobulin, begelomab, alefacept, aldesleukin, gevokizumab, daclizumab, basiliximab, ilostat, beperminogen activator plasmidperplasmid, sirukumab, tocilizumab, clazakizumab, mepolizumab, fingolimod, panobinostat, tricirbine, nilotinib, imatinib, tofacitinib, momelotinib, peficitinib, itacitinib, infliximab, PEG-bHb-CO, etanercept, ixazomib, bortezomib, muromon ab), otelixizumab, gumarimus, bentuximab, ponesimod, KRP-203, FG-3019, emricasan, corticotropin, ibrutinib, cinryze, conestat, methoxy-peglycan erythropoietin beta, belimumab, blisibimod, atacicept, seliciclib, neihulizumab, everolimus, sirolimus, denileukindiftitox), LMB-2, natalizumab, catridecacog, cyclosporine, tacrolimus, voclosporin, voclosporin, canakinumab, mycophenolate mofetil, mizoribine, CE-1145, TK-DLI, abatacept, belatacept, olmesartan medoxomil, sparsentan, TXA-127, BIIB-023, alemtuzumab ( alemtuzumab, pentostatin, itolizumab, palifermin, leflunomide, PRO-140, cenicriviroc, fostamatinib, anifrolumab, sifalimumab, BAX-069, BG-00011, losmapi mod), QPI-1002, Shiga mAb, TZ-101, F-652, reparixin, ladarixin, PTX-9908, aganirsen, APH-703, sotrastaurin, sotrastaurin, milatuzumab, SM-101, T-Guard, APG-101, DEX-M74, cardiotrophin -1, tiprelestat, ASKP-1240, BMS-986004, HPH-116, KD-025, OPN-305, TOL-101, defibrotide, pomalidomide, rabbit anti-thymic immunoglobulin, laquinimod, remestemcel-L, horse anti-thymocyte immunoglobulin, Stempeucel, LIV-γ, Octagam10%, t2c-001, 99mTc, Clairyg, Prosorba, pomalidomide, laquinimod, teplizumab, FCRx, sornatide, foralumab, ATIR-101, BPX-501, ACP-01, ALLO-ASC-DFU, irbesartan + propagandam, ApoCell, RGI-2001, orotic acid, anti-CD3 bivalent antibody-diphtheria toxin conjugate, NOX-100, LT-1951, OMS721, ALN-CC5, ACH-4471, AMY-101, Acthar gel and CD4+CD25+ regulatory T cells, MEDI7814, P32, P59, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, CCX354, CCX721, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX587, CCX624, CCX282, CCX025, CCX507, CCX430, CCX765, CCX758, CCX771, CCX662, CCX650, and combinations thereof.

[0193] E. Preparation method

[0194] Crude compound 1 can be prepared as previously described. See, for example, WO2010 / 075257 and WO2016 / 053890, the contents of each of which are incorporated by reference in their entirety for all purposes.

[0195] The various salt forms described herein can be prepared as described in the examples provided. It should be understood that there can be more than one crystallization method to produce the tosylate, benzenesulfonate, naphthalenedisulfonate, naphthylate, camphorsulfonate and edisylate salt forms.

[0196] IV. Examples

[0197] The following examples are provided to help illustrate the described invention and are not intended to limit the scope of what the inventors regard as their invention.

[0198] Example 1: Benzenesulfonate of Compound 1 (Form I)

[0199]

[0200] In a 3-L round-bottom flask equipped with a magnetic stirrer, (2R, 3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (Compound 1, 250 g, 430 mmol) and MeCN (1.84 L, 8 vol) were added. The resulting mixture was stirred and heated to 75°C (internal temperature) for 30 minutes to form a clear solution, and filtered through a polyethylene frit filter and rinsed with MeCN (230 mL). To this solution, a pre-filtered solution of hydrated benzenesulfonic acid (77.9 g, 442 mmol (based on monohydrate), 1.03 eq) in MeCN (276 mL, 3 vol) was slowly added at a temperature of 60°C over 10 minutes and rinsed with MeCN (92 mL) (internal temperature dropped to 55°C). The resulting solution was cooled to 50°C, seeded with benzenesulfonate crystals of compound 1 (~100 mg), and slowly cooled to 45°C over 1 h. The resulting mixture was slowly cooled to RT and stirred for 42 h. The solid was collected by filtration, washed with MeCN (230 mL x 2), air-dried, and then dried in an oven under vacuum at 50°C overnight (48 h) to give N-cyclopentyl-4-((2R,3S)-1-(2-fluoro-6-methylbenzoyl)-3-((4-methyl-3-(trifluoromethyl)phenyl)-carbamoyl)piperidin-2-yl)phenylbenzenesulfonic acid ammonium salt as off-white crystals in a recovery of 266.5 g (84%). 1 H NMR(400MHz, DMSO-d6)(RT)δ10.44(s,1H),7.90–7.83(m,1H),7.65–6.95(m,14H),6.42–6.3 4(m, 1H), 6.05–5.00(br, 1H), 3.85–3.70(m, 1H), 3.22–3.00(m, 3H), 2.38–2.28(m, 4H), 2.20– 1.40 (m, 15H); (65°C) δ 10.22 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.68-6.70 (m, 15H), 6.44-6.35 (m, 1H), 3.72-3.65 (m, 1H), 3.25-2.98 (m, 3H), 2.40-2.28 (m, 4H), 2.22-1.40 (m, 15H). MS: (ES) m / z calculated value C 33 H 36 F4N3O2[m+H] + 582.3, the measured value is 582.2. XRPD picture is as follows Figure 1 The following Table 1 summarizes the significant peaks observed in the XRPD pattern. HPLC (achiral analysis and chiral): >99%. Elemental analysis was consistent with C39 H 41 Formula of F4N3O5S, KF: 0.66%.

[0201] Table 1: Notable peaks in Compound 1 benzenesulfonate (Form I)

[0202]

[0203] Differential Scanning Calorimetry (DSC) was performed on the collected crystals using a DSC25 from TA Instruments-Waters LLC. The sample was weighed into a standard aluminum pan and sealed with a standard aluminum lid with a pinhole. The measurement was completed using a scan rate of 10°C / min under a nitrogen purge. DSC analysis determined the melting point (onset) to be approximately 200.6°C (DSC). The DSC graph also showed an endothermic peak at around 207.2°C. The DSC thermogram is shown in Figure 1. Figure 2 shown.

[0204] TGA data were collected on a TA Instruments Q500 TGA. Each sample was loaded onto a pre-weighted platinum crucible; the balance and furnace were purged with nitrogen before analysis, with flow rates set to 40±5 and 60±5 mL / min, respectively. The heating process was programmed to start at ambient temperature and increase the temperature by 10°C / min. TGA analysis determined that Form I of the benzenesulfonate salt of Compound 1 exhibited a weight loss of approximately 0.14% when heated to approximately 202.9°C. The TGA thermogram is shown in Figure 1. Figure 2 shown (upper trace).

[0205] To evaluate the hygroscopicity and physical stability of the collected crystals at different humidities, dynamic vapor sorption (DVS) data were collected at 25°C after the samples were pre-equilibrated at 0% RH to remove unbound water. DVS was measured using a VTI SGA-100 vapor sorption analyzer. Adsorption and desorption data were collected in the range of 5% to 95% RH with 10% RH increments under a nitrogen purge. The equilibrium standard used for analysis was a weight change of less than 0.0100% in 5 minutes, with a maximum equilibrium time of 3 hours. The parameters of the DVS test are listed in Table 2.

[0206] Table 2: DVS test parameters

[0207]

[0208] DVS measurement diagram Figure 3 As shown. A weight change of 0.73% was measured from 5% to 95% relative humidity (RH). A weight change of about 0.5% was also measured from about 0% relative humidity (RH) to about 75% relative humidity. No changes in XRPD were observed before and after DVS measurement (data not shown).

[0209] The collected crystals were observed under magnification using a FEIQuanta 200 scanning electron microscope equipped with an Everhart Thornley (ET) detector. Images were collected and analyzed using xTm (v.2.01) and XT Docu (v.3.2) software, respectively. Magnification was verified using National Institute of Standards and Technology (NIST)-traceable standards. Samples were prepared for analysis by placing a small amount of sample on a carbon adhesive tab supported on an aluminum stand. The samples were then sputter coated twice (in different directions) with Au / Pd for 75 seconds using a Cressington 108 automated sputter coater at approximately 20 mA and 0.13 mbar (Ar). Representative images of the crystals are shown in Figure 2. Figure 4 When observed under a magnifying glass, the crystals are prismatic or anhedral, with sizes ranging from ~1 to 73 μm.

[0210] The collected crystals were observed under magnification using a polarizing microscope (Leica DM LP microscope equipped with a Spot Insight color camera). Different objectives were used with crossed polarizations and a first order red compensator to observe the samples. The sample was placed on a slide, a #1.5 cover glass was placed over the sample, and a drop of mineral oil was added. Images were acquired at ambient temperature using Spot Advanced software (v.4.5.9). A micrometer bar was inserted on the image as a size reference. Representative images of the crystals are shown in Figure 5 When observed under magnification, the crystals are needle-shaped, blade-shaped, and anhedral, ranging in size from ~2.5 to 83 μm.

[0211] The stability of the collected crystals was tested by storing them at 40°C and 75% relative humidity for 45 days. These conditions did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data not shown). Heating at 55°C for 24 hours or at 75°C for 1 week (open to air) in a vacuum oven did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data now shown). The physical form of both samples remained unchanged according to XRPD before and after testing (data not shown).

[0212] Example 2: Benzenesulfonate of Compound 1 (Form II)

[0213] In a 250-mL round-bottom flask equipped with a magnetic stirrer was added (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl)-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (Compound 1, 5.18 g, 8.9 mmol) and MeCN (70 mL, 14 vol). The resulting mixture was stirred and heated to 70°C (hot plate temperature) for 20 minutes to form a clear solution, and then cooled to 65°C (hot plate temperature). To this solution was slowly added a solution of benzenesulfonic acid hydrate (1.73 g, 9.81 mmol (based on monohydrate), 1.1 eq) in DI H2O (1.5 mL) and MeCN (15 mL) over 3 minutes and rinsed with MeCN (10 mL). The resulting solution was stirred at the same temperature for 15 minutes, then filtered through a polyethylene frit filter and rinsed with MeCN (10 mL). The resulting solution was stirred at 65°C (hot plate temperature) for 30 minutes, slowly cooled to room temperature and stirred overnight (18 hours). The resulting solution was seeded with benzenesulfonate crystals of compound 1 (~50 mg) and stirred at the same temperature for 2 hours. The solid was collected by filtration, washed with MeCN (15 mL x 2), air-dried (1 h), and then dried under high vacuum overnight (18 h) to obtain N-cyclopentyl-4-((2R,3S)-1-(2-fluoro-6-methylbenzoyl)-3-((4-methyl-3-(trifluoromethyl)phenyl)-carbamoyl)piperidin-2-yl)phenylbenzenesulfonic acid ammonium salt as off-white crystals with a recovery of 2 grams (30%). 1 HNMR(400MHz,DMSO-d6)(RT)δ10.44(s,1H),7.90–7.83(m,1H),7.65–7.25(m,10H),7.18–7.07(m,3H), 6.42–6.34(m,1H),4.85–4.00(br,2H),3.85–3.70(m,1H),3.22–3.00(m,3H),2.38–2.28(m,4H),2.20–

[0214] 1.40(m,15H));(65℃)δ10.22(d,J=84Hz,1H),7.85(d,J=8.4Hz,1H),7.68–

[0215] 7.56 (m, 3H), 7.44–7.20 (m, 6H), 7.18–6.70 (m, 4H), 6.44–6.35 (m, 1H), 6.20–5.20 (br, 2H), 3.72–3.65 (m, 1H), 3.25–2.98 (m, 3H), 2.40–2.28 (m, 4H)), 2.22–1.40 (m, 15H). MS: (ES) m / z calculated value C33 H 36 F4N3O2[M+H] + 582.3, found 582.2. The XRPD pattern is shown in Figure 6 The significant peaks observed in the XRPD pattern are summarized in Table 3 below. HPLC: >99%. Elemental analysis and formula C 39 H 41 F4N3O5S is consistent, KF: 0.42%.

[0216] Table 3: Notable peaks in the benzenesulfonate salt of compound 1 (form I)

[0217]

[0218] Differential Scanning Calorimetry (DSC) was performed as described in Example 1. DSC analysis determined the melting point (onset) to be about 180.5°C (DSC). The DSC graph also showed an endothermic peak at about 187.2°C. The DSC thermogram is shown in Figure 7 shown (lower trace).

[0219] TGA was performed as described in Example 1. TGA analysis determined that the besylate salt Form II of Compound 1 exhibited a weight loss of about 0.095% upon heating to about 189.5°C. The TGA thermogram is shown in Figure 7 shown (upper trace).

[0220] Example 3: Tosylate of Compound 1 (Form I)

[0221]

[0222] A 5-L three-necked flask equipped with an overhead stirrer was charged with (2R, 3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (Compound 1, 261.2 g, 449.1 mmol) and MeCN (2 L, 8 vol). The resulting mixture was stirred and heated to 75°C (internal temperature) for 20 minutes to form a clear solution. The solution was cooled to 65°C (internal temperature), and a solution of p-toluenesulfonic acid hydrate (1.25 hydrate corrected by KF analysis, 89.1 g, 458 mmol, 1.02 eq) in deionized water (45 mL, 0.5 vol) was slowly added over 20 minutes and rinsed with MeCN (45 mL x 2) (the internal temperature was maintained between 60 and 65°C). The resulting solution was stirred at the same temperature for 15 minutes, then filtered through a polyethylene frit filter and rinsed with MeCN (200 mL). The filtrate was cooled to 45 ° C and seeded with toluenesulfonate crystals of compound 1 (about 100 mg) and stirred at the same temperature for 1 h. The resulting mixture was slowly cooled to RT and stirred overnight (18 h). The solid was collected by filtration, washed with MeCN (250 mL x 2), air-dried (1 h), and then dried overnight (24 h) in an oven at 50 ° C under vacuum to provide N-cyclopentyl-4-((2R, 3S)-1-(2-fluoro-6-methylbenzoyl)-3-((4-methyl-3-(trifluoromethyl)phenyl)-carbamoyl)piperidin-2-yl)anilinium-4-methylbenzenesulfonate as off-white crystals with a recovery of 297.3 g (87%). 1H NMR (400MHz, DMSO-d6) (RT) δ10.45 (s, 1H), 7.89–7.85 (m, 1H), 7.65–7.53 (m, 1H), 7.53–7.41 (m, 4H), 7.38–7.27 (m, 2H), 7 .20–7.00(m, 5H), 6.42–6.36(m, 1H), 5.10–4.35(br, 2H), 3.85–3.70(m, 1H), 3.20–3.01(m, 3H), 2.40–2.30(m, 4H), 2.20– 2.21 (s, 1H); (65°C) δ 10.23 (d, J = 8.4 Hz, 1H), 7.85 (dd, J = 8.8, 2.0 Hz, 1H), 7.68-7.56 (m, 1H), 7.49 (J = 8.0 Hz, 2H), 7.44-6.89 (m, 11H), 6.43-6.37 (m, 1H), 3.81-3.73 (m, 1H), 3.26-2.99 (m, 3H), 2.40-2.30 (m, 5H), 2.28 (s, 3H), 1.98-1.40 (m, 14H). MS: (ES) m / z calculated value C 33 H 36 F4N3O2[M+H] + 582.3, the measured value is 582.2. XRPD picture is as follows Figure 8 The following Table 4 summarizes the significant peaks observed in the XRPD pattern. HPLC (achiral analysis and chiral): >99%. Elemental analysis was consistent with the chemical formula C 40 H 43 F4N3O5S, KF: 0.85%.

[0223] Table 4: Notable peaks in the tosylate salt form I of compound 1

[0224]

[0225] Differential Scanning Calorimetry (DSC) was performed as described in Example 1. DSC analysis determined the melting point (onset) to be about 206.2°C (DSC). The DSC graph also showed an endothermic peak at about 209.8°C. The DSC thermogram is shown in Fig. 9 shown (lower trace).

[0226] TGA was performed as described in Example 1. TGA analysis determined that the tosylate salt crystals of Compound 1 exhibited a weight loss of about 0.19% when heated to about 204.2°C. The TGA thermogram is shown in Fig. 9 shown (upper trace).

[0227] The hygroscopicity and physical stability of the collected crystals were measured using dynamic vapor sorption (DVS) as described in Example 1. The curve of the DVS measurement is shown in Fig.10 A weight change of 0.83% from 5% to 95% relative humidity (RH) was measured. A weight change of about 0.58% from about 0% relative humidity (RH) to about 75% relative humidity was also measured. No changes in XRPD were observed before and after DVS measurement (data not shown).

[0228] The collected crystals were observed using a scanning electron microscope (SEM) as described in Example 1. Representative images of the crystals are shown in Fig.11 When viewed under magnification, the crystals are blade-shaped, rod-shaped, or isodiametric, ranging in size from ~1 to 500 μm.

[0229] The collected crystals were observed using polarized light microscopy (PLM) as described in Example 1. Representative images of the crystals are shown in Fig.12 When viewed under magnification, the crystals are needle-, blade-, and other-shaped, ranging in size from -2.5 to 440 μm.

[0230] The stability of the collected crystals was tested by storing them at 40°C and 75% relative humidity for 45 days. These conditions did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data not shown). Heating at 55°C for 24 hours or 75°C for 1 week (open to air) in a vacuum oven did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data now shown). The physical form of both samples remained unchanged according to XRPD before and after testing (data not shown).

[0231] Example 4: Naphthalene disulfonate salt of compound 1 (crystalline form I)

[0232]

[0233] A 5-L three-necked flask equipped with an overhead stirrer was charged with (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl)-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (Compound 1, 261.2 g, 450 mmol) and MeCN (2 L, ~8 vol). The resulting mixture was stirred and heated to 75°C (internal temperature) for 20 minutes to form a clear solution, which was cooled to 70°C (internal temperature) and filtered through a polyethylene frit filter and rinsed with MeCN (200 mL). To this solution was slowly added over 25 minutes to a pre-filtered solution of naphthalene-1,5-disulfonic acid hydrate (89.2 g, 247.5 mmol (based on 4 hydrate (KF)), 0.6 eq) in DI H2O (90 mL, 1 vol) and MeCN (270 mL) (the reaction mixture became cloudy after adding 2 / 3 of the acid, at which time it was seeded with crystals of the naphthalene dimethanesulfonate salt of compound 1 (~100 mg)) and rinsed with 3% H2O in MeCN (50 mL) (internal temperature dropped to 65°C). The resulting mixture was stirred at 70°C for 40 minutes, and large pieces of solid formed were manually broken up by sight glass. The resulting mixture was slowly cooled to room temperature and stirred for 3 hours. The solid was collected by filtration, washed with 3% H2O in MeCN (250 mL x 2), MeCN (250 mL x 2), air-dried (1 h), and then dried in an oven under vacuum at 50 °C overnight (30 h) to give N-cyclopentyl-4-((2R,3S)-1-(2-fluoro-6-methylbenzoyl)-3-((4-methyl-3-(trifluoromethyl)phenyl)-carbamoyl)piperidin-2-yl)phenylnaphthalene-1,5-disulfonic acid ammonium salt as off-white crystals with a recovery rate of 299.4 g (91%). 1 H NMR(400MHz,DMSO-d6)(RT)δ10.44

[0234] (s,1H),8.83(d,J=8.8Hz 1H),7.95–7.80(m,2H),7.65–7.28(m,6H),7.19–

[0235] 7.00(m,3H),6.43–6.34(m,1H),4.55–3.95(br,2H),3.85–3.68(m,1H),3.25–2.99(m,3H),2.38–2.00(m,5H),1.90–

[0236] 1.40 (m, 14H); (65°C) δ10.21 (d, J = 8.8 Hz, 1H), 8.90 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 6.8 Hz, 1H), 7.89–7.82 (m, 1H), 7.68–7.58 (m, 1H), 7.46–7.20 (m, 5H), 7.16–6.70 (m, 4H), 6.44–6.35 (m, 1H), 5.80–5.20 (br, 1H), 3.80–3.64 (m, 1H), 3.22-2.98 (m, 3H), 2.40-2.00 (m, 6H), 1.96-1.40 (m, 13H). MS: (ES) m / z calculated value C 33 H 36 F4N3O2[M+H] + 582.3, found to be 582.2. The XRPD pattern is shown in Figure 1 Fig.13 The significant peaks observed in the XRPD pattern are summarized in Table 5 below. HPLC: >99%. Elemental analysis and C 38 H 39 The molecular formula of F4N3O5S is consistent; KF: 1.63%.

[0237] Table 5: Significant peaks in Compound 1 Naphthalene disulfonate Form I

[0238]

[0239] Differential scanning calorimetry (DSC) was performed as described in Example 1. DSC analysis determined the onset and peak melting temperatures of the endothermic peak to be 222.7°C and 232.8°C, respectively. The DSC thermogram is shown in Fig.14 shown (lower trace).

[0240] TGA was performed as described in Example 1. TGA analysis determined that Form I of the napthalene disulfonate salt of Compound 1 exhibited a weight loss of about 2.0% upon heating to about 233.1 °C. Fig.14 The TGA thermogram is shown (upper trace).

[0241] The hygroscopicity and physical stability of the collected crystals were measured using dynamic vapor sorption (DVS) as described in Example 1. The curves of the DVS measurements are shown in Fig.15 As shown. A weight change of 1.42% was measured from 5% to 95% relative humidity (RH). A weight change of about 0.6% was also measured from about 0% relative humidity (RH) to about 55% relative humidity. No changes in XRPD were observed before and after DVS measurement (data not shown).

[0242] The collected crystals were observed using a scanning electron microscope (SEM) as described in Example 1. Representative images of the crystals are shown at Fig.16 When viewed under magnification, the crystals are blade-shaped, rod-shaped, and equidiametric, ranging in size from ~1 to 150 μm.

[0243] The collected crystals were observed using polarized light microscopy (PLM) as described in Example 1. Representative images of the crystals are shown in Fig.17 When viewed under magnification, the crystals are circular, blade-shaped, or helium-shaped, ranging in size from about 1.3 to 75 μm.

[0244] The stability of the collected crystals was tested by storing them at 40°C and 75% relative humidity for 45 days. These conditions did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data not shown). Heating at 55°C for 24 hours or at 75°C for 1 week (open to air) in a vacuum oven did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data now shown). The physical form of both samples remained unchanged according to XRPD before and after testing (data not shown).

[0245] Example 5: Naphthalenesulfonate of Compound 1 (Crystal Form I)

[0246]

[0247] A 5-L three-necked flask equipped with an overhead stirrer was charged with (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (Compound 1, 263.3 g, 452.7 mmol) and MeCN (2 L, 8 vol). The resulting mixture was stirred and heated to 75° C. (internal temperature) for 15 minutes to form a clear solution, which was filtered through a polyethylene frit filter and rinsed with MeCN (200 mL). Under the condition of 70 ℃ (internal temperature), pre-filtered 2-naphthalenesulfonic acid hydrate (108g, 466.2mmol (based on 1.3 hydrate, KF), 1.03eq) in deionized water (54mL, 0.5vol) and MeCN (300mL) were slowly added to the solution in 25 minutes, soaked, and rinsed with MeCN (100mL) (internal temperature dropped to 64 ℃). The resulting solution was stirred at 65 ℃ for 40 minutes. The resulting mixture was slowly cooled to RT and stirred for 3 hours. The solid was collected by filtration, washed with MeCN (250 mL x 2), air-dried (1 h), and then dried in an oven under vacuum at 50 °C overnight (24 h) to afford N-cyclopentyl-4-((2R,3S)-1-(2-fluoro-6-methylbenzoyl)-3-((4-methyl-3-(trifluoromethyl)phenyl)-carbamoyl)piperidin-2-yl)phenylnaphthalene-2-sulfonic acid ammonium salt as off-white crystals in a recovery of 330.3 g (92%). 1 H NMR (400 MHz, DMSO-d6) RT )δ10.44(s, 1H), 8.12(s, 1H), 8.00-7.80(m, 4H), 7.70-7.28(m, 8H), 7.19-7.00(m, 3H), 6.43-6.34(m, 1 H), 4.80-4.10(br, 2H), 3.70-3.68(m, 1H), 3.40-2.99(m, 3H), 2.38-2.00(m, 5H), 1.90-1.40(m, 14H); ( 65 ℃ )δ10.21 (d, J=8.8 Hz, 1H), 8.13 (s, 1H), 7.99-7.78 (m, 4H), 7.75-7.20 (m, 8H), 7.18-6.64 (m, 4H), 6.42-6.36 (m, 1H), 5.80-5.20 (br, 1H), 3.25-2.98 (m, 3H), 2.40-2.00 (m, 6H), 1.96-1.40 (m, 13H). MS: (ES) m / z calculated value C 33 H 36 F4N3O2[m+H] +582.3, the measured value is 582.2. XRPD picture is as follows Fig.18 The following Table 6 summarizes the significant peaks observed in the XRPD pattern. HPLC (achiral analysis and chiral): >99%. Elemental analysis was consistent with the chemical formula C 43 H 43 F4N3O5S; KF: 0.79%.

[0248] Table 6: Notable peaks in the naphthoate salt form I of compound 1

[0249]

[0250] Differential Scanning Calorimetry (DSC) was performed as described in Example 1. DSC analysis determined the melting point (onset) to be about 211.7°C (DSC). The DSC graph also showed an endothermic peak at about 218.3°C. The DSC thermogram was shown at Fig.19 Middle (lower trace).

[0251] TGA was performed as described in Example 1. TGA analysis determined that the naphthalenesulfonate salt Form I of Compound 1 exhibited a weight loss of about 0.49% upon heating to about 217.0°C. The TGA thermogram is shown at Fig.19 Middle (upper trace).

[0252] The hygroscopicity and physical stability of the collected crystals were measured using dynamic vapor sorption (DVS) as described in Example 1. The curve of the DVS measurement is shown in Fig. 20 A weight change of 0.65% from 5% to 95% relative humidity (RH) was measured. A weight change of about 0.2% from about 0% relative humidity (RH) to about 55% relative humidity was also measured. No changes in XRPD were observed before and after DVS measurement (data not shown).

[0253] The collected crystals were observed using a scanning electron microscope (SEM) as described in Example 1. Representative images of the crystals are shown at Fig.21 When viewed under magnification, the crystals are blade-shaped, rod-shaped, and equants, ranging in size from ~1 to 150 μm.

[0254] The collected crystals were observed using polarized light microscopy (PLM) as described in Example 1. Representative images of the crystals are shown in Fig. 22 Middle. When viewed under magnification, the crystals appear blade-shaped and range in size from ~5 to 470 μm.

[0255] The stability of the collected crystals was tested by storing them at 40°C and 75% relative humidity for 45 days. These conditions did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data not shown). Heating at 55°C for 24 hours or at 75°C for 1 week (open to air) in a vacuum oven did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data now shown). The physical form of both samples remained unchanged according to XRPD before and after testing (data not shown).

[0256] Example 6: Camphorsulfonate of Compound 1 (Form I)

[0257]

[0258] A 1-L round-bottom flask equipped with a magnetic stirrer was charged with (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl)-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (Compound 1, 54.5 g, 94 mmol) and MeCN (400 mL, 8 vol). The resulting mixture was stirred and heated to 75°C (internal temperature) for 30 minutes to form a clear solution, cooled to 65°C (internal temperature) and filtered through a polyethylene frit filter and rinsed with MeCN (50 mL). To this solution was slowly added (1S)-(+)-10-camphorsulfonic acid (22.9 g, 98.06 mmol, 1.05 eq) in deionized water over 5 minutes.

[0259] The pre-filtered solution in H2O (11.5 mL, 0.5 vol) and MeCN (46 mL) was rinsed with MeCN (23 mL) (internal temperature dropped to 60 °C). The resulting solution was cooled to 55 °C, seeded with camphorsulfonic acid crystals of compound 1 (~50 mg) and stirred at the same temperature for 1 hour. The resulting mixture was slowly cooled to room temperature and stirred for 3 hours. The solid was collected by filtration, washed with 2% H2O in MeCN (50 mL x 2), MeCN (50 mL x 2) solution, air-dried (1 h), and then dried in a vacuum oven at 50 °C overnight (24 h) to give N-cyclopentyl-4-((2R, 3S)-1-(2-fluoro-6-methylbenzoyl)-3-((4-methyl-3-(trifluoromethyl)phenyl)-carbamoyl)piperidin-2-yl)anilinium (1S)-(+)-10 camphorsulfonic acid salt as off-white crystals with a recovery of 69 g (90%). 1 H NMR (400 MHz, DMSO-d6) RT )δ10.45(s,1H),7.90–

[0260] 7.82(m,1H),7.65–7.48(m,3H),7.38–7.07(m,6H),6.42–

[0261] 6.34(m,1H),5.90–5.20(br,1H),3.85–3.70(m,1H),3.22–

[0262] 3.00(m,3H),2.85(d,J=14.7Hz,1H),2.71–2.58(m,1H),2.40–

[0263] 1.98(m,8H),1.94–1.40(m,17H),1.31–1.18(m,2H),1.02(s,3H),0.71(s,3H); ( 65 ℃ )δ10.22(d,J=8.4Hz,1H),7.89–7.81(m,1H),7.68–7.56(m,1H),7.46–7.25(m,4H),7.18–6.80(m,5H),6.42–6.34(m,1H),3.81–3.72(m,1H),3.26–2.99(m,3H),2.90(d,J=14.7Hz,1H),2.75–2.62(m,1H)),2.48–2.00(m,8H),1.94–1.40(m,17H),1.35–1.20(m,2H),1.06(s,3H),0.75(s,3H). MS:(ES) m / z calculated value C 33 H 36 F4N3O2[M+H] + 582.3, found to be 582.2. XRPD: The XRPD pattern is shown in Fig.23 The significant peaks observed in the XRPD pattern are summarized in Table 7 below. HPLC: >99%. Elemental Analysis and Chemical Formula C 43 H 51 F4N3O6S is consistent, KF: 1.09%.

[0264] Table 7: Notable peaks in the camphorsulfonate salt form I of compound 1

[0265]

[0266] Differential Scanning Calorimetry (DSC) was performed as described in Example 1. DSC analysis determined the melting point (onset) to be about 202.8°C (DSC). The DSC graph also showed an endothermic peak around 209.8°C. Fig.24 The DSC thermogram is shown (lower trace).

[0267] TGA was performed as described in Example 1. TGA analysis determined that Form I of the camphorsulfonate salt of Compound 1 exhibited a weight loss of about 0.23% upon heating to about 205.0°C. Fig.24 The TGA thermogram is shown (upper trace).

[0268] The hygroscopicity and physical stability of the collected crystals were measured using dynamic vapor sorption (DVS) as described in Example 1. The curves of the DVS measurements are shown in Fig.25 A weight change of 0.96% from 5% to 95% relative humidity (RH) was measured. A weight change of about 0.35% from about 0% relative humidity (RH) to about 65% relative humidity was also measured. No changes in the XRPD were observed before and after the DVS measurement (data not shown).

[0269] The collected crystals were observed using a scanning electron microscope (SEM) as described in Example 1. Representative images of the crystals are shown in Fig.26 When viewed under magnification, the crystals are blunt-ended blade-shaped and rod-shaped, ranging in size from -<1 to 77 μm.

[0270] The collected crystals were observed using polarized light microscopy (PLM) as described in Example 1. Representative images of the crystals are shown in Fig. 27 When viewed under magnification, the crystals are soft agglomerates, acircular, flat plates, and anhedral shapes, ranging in size from -2.5 to 84 μm.

[0271] The stability of the collected crystals was tested by storing them at 40°C and 75% relative humidity for 45 days. These conditions did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data not shown). Heating at 55°C for 24 hours or at 75°C for 1 week (open to air) in a vacuum oven did not result in any significant decomposition as shown by HPLC, LCMS and NMR analysis (data now shown). The physical form of both samples remained unchanged according to XRPD before and after testing (data not shown).

[0272] Example 7: Ethylenedisulfonate of Compound 1 (Form I)

[0273]

[0274] A 200 mL round bottom flask equipped with a magnetic stirrer was charged with (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide (CCX168 lot#D-15-012, 10 g, 17.2 mmol) and MeCN (120 mL, 12 vol). The resulting mixture was stirred and heated to 65 °C (internal temperature) for 30 minutes to form a clear solution. To this solution was slowly added 1,2-ethanedisulfonic acid dihydrate (1.97 g, 8.6 mmol, 0.5 eq) in portions. The resulting solution was stirred at the same temperature for 30 minutes and then cooled to room temperature. The mixture was concentrated to dryness in vacuo and then placed under high vacuum overnight.

[0275] EtOH (100 mL, 10 V) was added to the dried solid. The mixture was heated at 80 ° C (internal temperature) for 1 hour. The solution was slowly cooled to room temperature and stirred overnight. The solid was collected by filtration, washed with EtOH (20 mL x2), and then dried under high vacuum overnight to obtain N-cyclopentyl-4-((2R, 3S)-1-(2-fluoro-6-methylbenzoyl)-3-((4-methyl-3-(trifluoromethyl)phenyl)carbamoyl)piperidin-2-yl)phenyl-1,2-disulfonic acid ammonium salt as off-white crystals with a recovery of 8.94 g (77%). 1 H NMR(400MHz, DMSO-d6)10.45(s,1H),7.85(dd,J=10.8,2.2Hz,1H),7.68–7.47(m,3H),7.39–7.22(m,4H),7.20–7. 00(m,2H),6.41(dd,J=11.3,6.2Hz,1H),3.81(m,J=6.6Hz,1H),3.23–3.02(m,3H),2.69(s,2H),2.33(m,5H),2.22–

[0276] 2.00(m,1H),1.87(s,3H),1.85–1.72(m,3H),1.72–1.63(m,2H),1.62–

[0277] 1.45 (m, 5H). MS: (ES) m / z calculated value C 33 H 36 F4N3O2[M+H] + 582.3, the measured value is 582.2. XRPD picture is as follows Fig.28 The significant peaks observed in the XRPD pattern are summarized in Table 8 below. HPLC: >99%. Elemental Analysis and Chemical Formula C 68 H 76 F8N6O10 S2 is consistent, KF: 1.13%.

[0278] Table 8: Notable peaks in the ethylenedisulfonate form I of compound 1

[0279]

[0280] Differential Scanning Calorimetry (DSC) was performed as described in Example 1. DSC analysis determined the melting point (onset) to be about 205.2°C (DSC). The DSC graph also showed an endothermic peak at about 213.3°C. The DSC thermogram was shown at Fig.29 middle.

[0281] Example 8: Aqueous Suspension Formulation Using the Salt Form of Compound 1

[0282] An in vivo PK study in rats was conducted to compare the PK profile and bioavailability of the free base crystalline form of Compound 1 with various salt forms of Compound 1 in an aqueous liquid suspension formulation containing 0.5% w / v hydroxypropylcellulose (Klucel GF) and 0.5% w / v poloxamer F-68 (BASF Kolliphor P188). Each animal was orally administered 10 mg / kg of Compound 1 at a dosing volume of 5 mL / kg (dosing concentration of 2 mg / mL). Table 9 summarizes the measured PK parameters. The PK profiles of these formulations are shown in Table 9. Fig.30 shown.

[0283] Table 9: Comparison of PK exposure in rats

[0284]

[0285] Example 9: Aqueous Suspension Formulation Using the Salt Form of Compound 1

[0286] An in vivo PK study in rats was conducted to compare the PK profile and bioavailability of the free base crystalline form of Compound 1 with various salt forms of Compound 1 in an aqueous liquid suspension formulation containing 1% HPMC. Each animal was orally administered 10 mg / kg of Compound 1 at a dosing volume of 5 mL / kg (dosing concentration of 2 mg / mL). Table 10 summarizes the measured PK parameters. The PK profiles of these formulations are shown in Table 10. Fig.31 shown.

[0287] Table 10: Comparison of PK exposure in rats

[0288]

[0289] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, those skilled in the art will appreciate that certain changes and modifications may be implemented within the scope of the appended claims. In addition, each reference provided is incorporated by reference in its entirety to the same extent as if each reference were incorporated by reference individually. In the event of a conflict between the present application and the reference provided, the present application shall prevail.

Claims

1. A naphthalene disulfonate salt crystal form I of compound 1, It is characterized in that The X-ray powder diffraction (XRPD) pattern includes peaks at 6.5, 7.0, 12.4, 14.7, 15.2, and 18.0 degrees 2Θ (± 0.2 degrees 2Θ).

2. The naphthalene disulfonate crystal form I as claimed in claim 1, which is in a single crystal form and substantially does not contain other crystal forms or amorphous forms.

3. The naphthalene disulfonate salt form I as claimed in claim 1, further characterized in that: XRPD peaks at 9.6, 11.2, 18.6 and 20.4 degrees 2Θ (± 0.2 degrees 2Θ).

4. The naphthalene disulfonate crystal form I according to claim 1, characterized in that: It is basically consistent with the X-ray powder diffraction pattern in FIG13 .

5. The naphthalene disulfonate salt form I as claimed in claim 1, further characterized in that: The differential scanning calorimetry thermogram (DSC) included an endothermic peak at about 232.8°C.

6. The naphthalene disulfonate crystal form I as claimed in claim 1, further characterized in that: Melting point onset of about 222.7°C as determined by differential scanning calorimetry thermogram (DSC).

7. The naphthalene disulfonate crystal form I according to claim 1, characterized in that: The DSC thermogram substantially conforms to FIG. 14 .

8. The naphthalene disulfonate salt form I as claimed in claim 1, further characterized in that: The weight loss was about 2.0% when heated to about 233.1°C as measured by thermogravimetric analysis (TGA).

9. The naphthalene disulfonate salt form I as claimed in claim 1, further characterized in that: This is basically consistent with the thermogravimetric analysis (TGA) thermogram of FIG14 .

10. The naphthalene disulfonate crystal form I as claimed in claim 1, further characterized in that: After dynamic vapor sorption cycling from about 0% relative humidity (RH) to about 55% RH at 25°C, the weight gain was about 0.6%.

11. The naphthalene disulfonate crystal form I as claimed in claim 1, further characterized in that: After dynamic vapor sorption cycling from about 5% relative humidity (RH) to about 95% RH at 25°C, the weight gain was about 1.42%.

12. The naphthalene disulfonate salt form I of claim 1, which has a dynamic vapor adsorption curve substantially as shown in FIG.

15.

13. The naphthalene disulfonate salt form I according to claim 1, further characterized in that: The scanning electron microscope (SEM) images are mainly blade-shaped, rod-shaped or equal-diameter particles.

14. The naphthalene disulfonate salt Form I of claim 1, wherein the particle size measured by scanning electron microscopy (SEM) is about 1 to 150 μm.

15. The naphthalene disulfonate crystal form I as claimed in claim 1, further characterized in that: This is substantially consistent with the scanning electron microscope (SEM) image of FIG. 16 .

16. The naphthalene disulfonate salt form I as claimed in claim 1, further characterized in that: The particles ranged in size from about 1.3 to 75 μm as determined by polarized light microscopy (PLM).

17. The naphthalene disulfonate crystal form I as claimed in claim 1, further characterized in that: A polarized light microscopy (PLM) profile essentially as shown in FIG17 .

18. A pharmaceutical composition comprising a salt form of Compound 1 as claimed in claim 1 and at least one pharmaceutically acceptable excipient.

19. An oral pharmaceutical composition prepared using the naphthalenedisulfonate crystal form I of Compound 1 as claimed in claim 1.

20. An aqueous suspension comprising the naphthalenedisulfonate crystalline form I of Compound 1 as claimed in claim 1 and at least one excipient.

21. An injectable or infusible solution comprising Compound 1 and at least one wetting agent or solvent, characterized in that The injectable or infusible solution is prepared using the naphthalenedisulfonate crystal form I of Compound 1 as claimed in claim 1.

22. Use of the naphthalenedisulfonate salt form I of Compound 1 as claimed in claim 1 in the preparation of a medicament for treating a disease or condition involving or susceptible to pathological activation of C5a receptors, characterized in that: The disease or disorder is an autoimmune disorder, an inflammatory disorder, a cardiovascular or cerebrovascular disorder, vasculitis, HIV infection, AIDS, a neurodegenerative disorder, or cancer.

23. The use according to claim 22, characterized in that The disease or disorder is selected from the group consisting of anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis, C3 glomerulopathy, hidradenitis suppurativa, and lupus nephritis.

24. The use according to claim 22, characterized in that The disease or disorder is anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis.

25. The use according to claim 22, characterized in that The disease or condition is granulomatosis with polyangiitis.

26. The use according to claim 22, characterized in that The disease or condition is microscopic polyangiitis.

Citation Information

Patent Citations

  • Microporous-semipermeable laminated osmotic system

    US4256108A

  • C5ar antagonists

    WO2010075257A1

  • PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS

    WO2016053890A1